GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD.

Guangdong Zhongsheng Pharmaceutical Co., Ltd.

002317

CNE100000HW4

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
14.9 ^CNY	+2.19%		+3.98%	-7.17%

Apr. 22	Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 11	Zhongsheng Pharma's Chairman to Raise Stake in Company	MT

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Final Dividend Profit Distribution Proposal for 2022

April 11, 2023 at 03:57 pm EDT

Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced on 11 April 2023 the Final Dividend profit distribution proposal for 2022 of Cash dividend/10 shares (tax included): CNY 2.00000000.

Latest news about Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Zhongsheng Pharma's Chairman to Raise Stake in Company	Mar. 11	MT
Zhongsheng Pharma's Unit Gets Nod to Market Mirabegron	Jan. 18	MT
Zhongsheng Pharma Chairman Plans Boosting Stake	Dec. 08	MT
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Zhongsheng Pharmaceutical Gets Drug Registration Certificate for Carbocysteine Oral Solution	23-10-18	MT
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Zhongsheng Pharmaceutical Gets Nod to Register Moxifloxacin Hydrochloride Eye Drops	23-07-31	MT
Zhongsheng Pharma Registers Mucolytic in China	23-07-06	MT
Zhongsheng Pharmaceutical Unit Completes Phase III Clinical Trial of Flu Drug	23-07-03	MT
Guangdong Zhongsheng Pharmaceutical Co., Ltd.(SZSE:002317) added to Shenzhen Stock Exchange Component Index	23-06-12	CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd.(SZSE:002317) added to Shenzhen Stock Exchange Component A Share Index	23-06-12	CI
Zhongsheng Pharma Enrols Subjects in Phase IIb Clinical Trial of NASH Drug	23-06-05	MT
Zhongsheng Pharm Unit Enrolls First Subject for RAY1225 Injection Trial	23-05-22	MT
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 May 2023	23-05-10	CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022	23-05-08	CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Final Dividend Profit Distribution Proposal for 2022	23-04-11	CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-10	CI
Zhongsheng Pharma Gets Conditional Market Approval For Oral COVID-19 Drug	23-03-27	MT
Guangdong Zhongsheng Pharmaceutical Enrolls Patients in Clinical Trial of Flu Drug	23-03-17	MT
Guangdong Zhongsheng Pharm Gets Nod to Trial Diabetes Drug	23-03-14	MT
Zhongsheng Pharma Gets Regulatory Nod for Registration of Eye Drops	23-02-10	MT
Guangdong Zhongsheng Pharm Makes Progress in Clinical Trial of COVID-19	23-01-02	MT
Guangdong Raynovent Biotechnology Co., Ltd announced that it has received CNY 370 million in funding from Shenzhen Qianhai Xinyi Yide Fund Management Co., Ltd., Efung Capital, Guangdong Zhongsheng Pharmaceutical Co., Ltd., Lake Bleu Capital (Hong Kong) Limited, Guangzhou Guoju Venture Capital Co., Ltd., Wanlian Guangsheng Investment Co., Ltd.	23-01-02	CI

Chart Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Duration

Period

Chart Guangdong Zhongsheng Pharmaceutical Co., Ltd.

More charts

Guangdong Zhongsheng Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, manufacture and distribution of medicines. The Companyâs medicine products are categorized into Chinese patent medicines, chemical drugs, chemical bulk drugs and herbal decoction pieces, which include capsules for thrombus, pellets for upper respiratory tract diseases, granular for sunstroke, compound dexamethasone acetate creams and azelastine hydrochloride eye drops, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

14.9

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD.	-7.17%	1.74B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals